Company intelligence / Profile preview

Kanabo

London, England, United Kingdomkanabogroup.com ↗

Ownership: Private
Employees: ~22
Development stage: Commercial

Overview

Kanabo has developed and commercialized cannabis-derived formulations and medical-grade vaporization devices. The company has a patent-pending sleep formula and formulas targeting CNS disorders. Initial products are being sold in Europe; clinical validation studies have been conducted on their VapePod device. They also operate telehealth platforms for online consultations and prescriptions.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule (cannabinoids such as THC and CBD)Device (therapeutic inhalation/vaporization device)Combination product (formulation + device)
Industry: Biotech

Drug pipeline

3 assets

Focus

Commercial

Indications: CNS disorders

2 more assets in the full pipeline.

Request access →

Partnerships

Not specified in public sources.

Beyond the preview

Go deeper on Kanabo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kanabo.

Explore the full profile